


LISTING OF CLAIMS:



This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1. (Currently Amended) A method for treating a host infected with respiratory syncytial virus (RSV) comprising administering to a host in need thereof an ~~anti~~ RSV effective amount of a compound of ~~Formula 1~~:



or



(+)

or a pharmaceutically acceptable salt thereof[.]

wherein:


R_1 is selected from the group consisting of NHC(O)Y , where Y is $\text{C}_1\text{-C}_{22}$ alkyl, $\text{C}_2\text{-C}_{22}$ alkenyl, and $\text{C}_2\text{-C}_{22}$ alkynyl;

R_2 is selected from the group consisting of OX , where X is $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, and $\text{C}_2\text{-C}_8$ alkynyl; and

R_3 is phosphocholine.


2. (Currently Amended): The method of claim 1, wherein the compound is

Y is $\text{C}_1\text{-C}_{14}$ alkyl




Claims 3-5. (Cancelled).

6. (Currently amended): The method of claim 1, wherein the compound is



~~3-dodecanamido 2-ethoxypropyl 1-phosphocholine;~~



~~3-decanamido 2-ethoxypropyl 1-phosphocholine.~~

7. (Previously presented): The method of claim 1 wherein the host is a mammal.
8. (Previously presented): The method of claim 1 wherein the host is a human.

Claims 9-38. (Cancelled).

39. (Previously presented): The method of claim 1, wherein the administering is orally, intravenously, parentally, intradermally, subcutaneously, topically, or by inhalation.